The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $31.67

Today's change+0.06 +0.19%
Updated August 28 4:05 PM EDT. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $31.67

Today's change+0.06 +0.19%
Updated August 28 4:05 PM EDT. Delayed by at least 15 minutes.

AstraZeneca PLC up (U.S.)$0.06

AstraZeneca PLC closed up Friday by (U.S.)$0.06 or 0.19% to (U.S.)$31.67. Although unchanged over the last five days, shares are down 10.00% for the last year to date. This security has underperformed the S&P 500 by 14.29% during the last year.

Key company metrics

  • Open(U.S.) $31.43
  • Previous close(U.S.) $31.61
  • High(U.S.) $31.71
  • Low(U.S.) $31.40
  • Bid / Ask-- / --
  • YTD % change-10.00%
  • Volume1,735,450
  • Average volume (10-day)2,037,629
  • Average volume (1-month)1,954,534
  • Average volume (3-month)2,531,635
  • 52-week range(U.S.) $29.50 to (U.S.) $38.12
  • Beta0.73
  • Trailing P/E67.94×
  • P/E 1 year forward14.86×
  • Forward PEG6.07×
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield4.42%
  • Trailing EPS(U.S.) $0.47
Updated August 28 4:05 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
0.00%

Based on its net profit margin of 4.61%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue6,3076,0576,6836,542
Total other revenue--------
Total revenue6,3076,0576,6836,542
Gross profit5,2984,8315,0515,184
Total cost of revenue1,0091,2261,6321,358
Total operating expense5,3845,1247,0326,001
Selling / general / administrative2,5852,4583,0662,767
Research & development1,3561,2801,3601,275
Depreciation / amortization376265306342
Interest expense (income), net operating--------
Unusual expense (income)3433211,027515
Other operating expenses, total-285-426-359-256
Operating income923933-349541
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax658678-580322
Income after tax696552-321253
Income tax, total-38126-25969
Net income697550-321254
Total adjustments to net income--------
Net income before extra. items697550-321254
Minority interest1-201
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items697550-321254
Inc. avail. to common incl. extra. items697550-321254
Diluted net income697550-321254
Dilution adjustment--00--
Diluted weighted average shares1,2651,2651,2621,264
Diluted EPS excluding extraordinary itemsvalue per share0.550.43-0.250.20
Dividends per sharevalue per share0.950.001.900.00
Diluted normalized EPSvalue per share0.830.700.820.78